UroGen Pharma   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: New York NY United States (2004)

Organization Overview

First Clinical Trial
2013
NCT01803295
First Marketed Drug
2020
mitomycin (mutamycin)
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

iklein@urogen.com | UroGen-Parma LTD | UroGen Pharma | UROGEN PHARMA | UroGen Pharma Ltd.

Active Ingredients

Marketed Drugs (1)

mitomycin (mutamycin) (2020)

Drugs in Phase 3 Trials (1)

mitomycin (mutamycin) (9 trials)

Drugs in Phase 2 Trials (2)

Key: UroGen Pharma (1) Acquired (1)

imiquimod (aldara) (2 trials)

rimabotulinumtoxinB (Myobloc) (1 trial)

Drugs in Phase 1 Trials (1)

zalifrelimab (1 trial)

Drugs in Other Trials (1)

water (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 3)

Carcinoma, Transitional Cell (Phase 3)

Enuresis (Phase 2)

Neoplasms (Phase 2)

Recurrence (Phase 2)

Urinary Bladder Diseases (Phase 2)

Urinary Bladder Neoplasms (Phase 3)

Urinary Bladder, Overactive (Phase 2)

Urinary Incontinence (Phase 2)

Urologic Diseases (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 13
  • # of Trial APIs: 5